Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs

NewsGuard 100/100 Score
Apr 21 2010

Icagen, Inc. (Nasdaq:ICGN) today announced that results from a study of ICA-105665 in patients with photosensitive epilepsy will be presented at the Tenth Eilat Conference on New Antiepileptic Drugs on Tuesday, April 27, 2010 in Eilat, Israel. The presentation will be made by Dorothee Kasteleijn-Nolst Trenite, MD, University Medical Centre Utrecht and Universita di Roma Sapienza II, Rome, Italy. Dr. Kasteleijn-Nolst Trenite is an internationally recognized expert on studies of photosensitivity as proof of concept for new anti-epileptic drugs and served as the central electroencephalogram (EEG) reader for the study. The topline results of the study were the subject of a previous press release by Icagen.

SOURCE Icagen, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , ,

Comments (0)

Suggested Reading

Innovative malaria prodrug targets liver, enhances efficacy while reducing toxicity, preclinical studies show
Study unlocks genetic secrets in APOEε4 carriers that could defend against Alzheimer's
Are we eating what's really good for us? New insights into macronutrients and chronic disease
Examining how pain could play a direct protective role in the gut
Study finds microdosing LSD leads to longer sleep: Insights from a controlled trial
New research sheds light on how GLP-1 obesity drugs may change food cravings
Study finds erectile dysfunction drugs linked to lower Alzheimer's risk
Study shows antipsychotic drugs increase health risks in dementia patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
From gut to mind: Exploring prebiotics and probiotics as dual fighters against depression and obesity